Sangamo, Prevail Therapeutics ink deal for evaluating AAV capsids

Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The ... Read More